James Moore: Deals look better for the prey than the predator
Outlook AstraZeneca and Yahoo could be corporate twins. They operate in very different sectors but the problems facing both are remarkably similar, and so are the drugs their respective chief executives have settled upon to treat what ails them.
Both are big, wealthy, cash rich, businesses facing flat or declining revenues while struggling to find replacements for products which are losing either patent protection, or relevance, or both.
Both are now hoping that they can buy their way out of their difficulties. That means paying vastly over the odds for companies which have potential but not much beyond that.
Yahoo's recent acquisition of Tumblr, the blogging site which has a popular product but which doesn't make much out of it, is very much in that category.
Meanwhile Astra, which has been doing much the same thing with a string of biotechnology acquisitions, added to its number yesterday with Omthera Pharmaceuticals, whose speciality is fish oil-derived heart medicines.
Its lead drug has at least completed the final stage of its trials, although it still has to secure final US regulatory approvals, but this is hardly new news.
Even after the announcement of the successful trials, the market valued the company at significantly less than Astra paid for it. The purchase price represents an 88 per cent premium to Omthera's Friday close on the Nasdaq.
It's true that heart drugs are a speciality of AstraZeneca and Omthera's product could be combined with the former's cholesterol treatment Crestor. But, as with Yahoo it's very much could, might, if, maybe. And even if the products of their new playthings are winners, both these giants have to prove they can successfully exploit them. Big companies that buy smaller companies, even in industries that put a premium on innovation like the internet or pharmaceuticals, sometimes struggle to do that.
Their shareholders have to hope that their respective spending binges yield a winner or two, because so far the deals they've done look much better for the prey than the predator – prey that could easily be selling snake oil, rather than fish oil, when it comes to making a return for the predator's shareholders.
- 1 I've been called an abusive and dangerous parent, when all I did was listen to my transgender child
- 2 Company breaks open Apple Watch to discover what it says is 'planned obsolescence'
- 3 Teaching profession headed for crisis as numbers continue to drop and working lives become 'unbearable'
- 4 The most powerful passports in the world
- 5 Chinese student carries disabled friend to school every day for three years
Nepal earthquake: How you can help victims of the Kathmandu disaster
Nepal earthquake in pictures: Photos show devastation caused by 7.8 magnitude earthquake
Royal baby: Live updates as superbug closes ward at St Mary's Hospital in London where Duchess of Cambridge is due to give birth
Teaching profession headed for crisis as numbers continue to drop and working lives become 'unbearable'
General Election 2015: The photo of a tree that proves the Tories have an image problem
General Election 2015: Chuka Umunna on the benefits of immigration, humility – and his leader Ed Miliband
The sickening truth about food banks that the Tories don't want you to know
Migrant boat disaster: Ukip candidate mocks victims in sickening Twitter post
Nigel Farage wants the BBC to stop making programmes like Doctor Who, Strictly Come Dancing, and Top Gear
Global warming: Scientists say temperatures could rise by 6C by 2100 and call for action ahead of UN meeting in Paris
General Election 2015: Britain would become a 'communist dictatorship' under Ed Miliband and Nicola Sturgeon, claims wife of Michael Gove
iJobs Money & Business
£24000 - £26000 per annum + benefits : Ashdown Group: A highly successful, glo...
£50000 - £55000 per annum: Ashdown Group: Business Analyst - Financial Service...
£18000 - £23000 per annum + OTE £45K: SThree: At SThree, we like to be differe...
£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is the o...